Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.

Yoshikane NonagaseMasayuki TakedaKoichi AzumaHidetoshi HayashiKoji HarataniKaoru TanakaKimio YonesakaHidenobu IshiiTomoaki HoshinoKazuhiko Nakagawa

Published in: Thoracic cancer (2019)

Plasma concentrations of AXL and GAS6 do not reflect tumor expression levels, and their measurement is thus not a viable alternative to direct analysis of tumor tissue in EGFR-mutated NSCLC.

Keyphrases

small cell lung cancer
tyrosine kinase
epidermal growth factor receptor
poor prognosis
room temperature
carbon dioxide
replacement therapy
ionic liquid